Inventor · disambiguated record
Michael Diem
Also filed as: DIEM MICHAEL
21 granted patents·4 pending applications·97 citations·filing 2011–2023
94Inventor score
Top patents by PatentIndex Score
25 records- 0196US9897612B2Fibronectin type III repeat based protein scaffolds with alternative binding surfacesJANSSEN BIOTECH INC·Filed 2015·Granted Feb 20, 2018·12 cites·7 claims
- 0295US10925932B2Serum albumin-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Feb 23, 2021·8 cites·16 claims
- 0394US10597438B2PD-L1 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Mar 24, 2020·12 cites·17 claims
- 0493US9200273B2Fibronectin type III repeat based protein scaffolds with alternative binding surfacesDIEM MICHAEL·Filed 2012·Granted Dec 1, 2015·20 cites·8 claims
- 0591US10611823B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Apr 7, 2020·12 cites·11 claims
- 0690US9695228B2EGFR and c-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2013·Granted Jul 4, 2017·15 cites·9 claims
- 0789US10662235B2Cysteine engineered fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted May 26, 2020·4 cites·15 claims
- 0887US11833190B2Serum albumin-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2021·Granted Dec 5, 2023·1 cites·11 claims
- 0986US10844122B2Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereofJANSSEN BIOTECH INC·Filed 2016·Granted Nov 24, 2020·4 cites·8 claims
- 1083US9725497B2EGFR and C-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2013·Granted Aug 8, 2017·5 cites·13 claims
- 1182US11345739B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted May 31, 2022·1 cites·20 claims
- 1280US11787875B2Materials and methods for improved single chain variable fragmentsJANSSEN BIOTECH INC·Filed 2020·Granted Oct 17, 2023·1 cites·26 claims
- 1378US12258385B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2022·Granted Mar 25, 2025·0 cites·9 claims
- 1477US11466082B2Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2019·Granted Oct 11, 2022·2 cites·21 claims
- 1574US12304939B2EGFR and C-met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2021·Granted May 20, 2025·0 cites·8 claims
- 1669US12054534B2Prostate specific membrane antigen binding fibronectin type iii domainsJANSSEN BIOTECH INC·Filed 2020·Granted Aug 6, 2024·0 cites·14 claims
- 1769US2024067754A1Materials and methods for improved single chain variable fragmentsJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1868US10571472B2Fibronectin type III repeat based protein scaffolds with alternative binding surfacesJANSSEN BIOTECH INC·Filed 2017·Granted Feb 25, 2020·0 cites·5 claims
- 1965US10954284B2EGFR and c-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted Mar 23, 2021·0 cites·6 claims
- 2064US11447539B2PD-L1 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted Sep 20, 2022·0 cites·13 claims
- 2159US10844111B2Prostate specific membrane antigen binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2016·Granted Nov 24, 2020·0 cites·13 claims
- 2258US2020325210A1Cysteine engineered fibronectin type iii domain binding moleculesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 2357US2025320304A1Compositions comprising enhanced multispecific binding agents for an immune responseJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2451US2022356266A1Biosynthetic glycoprotein populationsJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2545US8415306B2Insulin-like growth factor 1 receptor binding peptidesDIEM MICHAEL·Filed 2011·Granted Apr 9, 2013·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Michael Diem files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →